143741-67-7

Basic information

• Product Name: 1H-Isoindole-1,3(2H)-dione, 2-(4-phenyl-3-butenyl)-
• CAS NO: 143741-67-7
• Molecular Formula: C18H15NO2
• Molecular Weight: 277.323
• Mol File: 143741-67-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Isoindole-1,3(2H)-dione, 2-(4-phenyl-3-butenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindole-1,3(2H)-dione, 2-(4-phenyl-3-butenyl)-(143741-67-7)
• EPA Substance Registry System: 1H-Isoindole-1,3(2H)-dione, 2-(4-phenyl-3-butenyl)-(143741-67-7)

Safety Data

• Hazardous Substances Data: 143741-67-7(Hazardous Substances Data)

Usage

Type

Chemical compound

Derivative

Sulfanilamide

Use

Antimicrobial agent in veterinary medicine

Mechanism of action

Inhibits the growth of bacteria

Common use

Treat infections in animals

Classification

Sulfonamide class of antibiotics

Upstream product

• 10229-11-5 4-phenyl-but-3-yn-1-ol 
• 136918-14-4 phthalimide 
• 770-36-5 4-phenylbuta-3-en-1-ol 
• 591-50-4 iodobenzene 
• 52898-32-5 N-(3-butenyl)phthalimide 
• 71-43-2 benzene 
• 66417-43-4 (2,6-dimethoxyphenyl)diphenylphosphine 
• 84812-12-4 (2,6-dimethoxyphenyl)diphenyl(3-phthalimidopropyl)phosphonium bromide 
• 100-52-7 benzaldehyde 
• 7743-29-5 [3-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-propyl]-triphenyl-phosphonium bromide 

Downstream Products

• 54981-87-2 2-(4-phenylbutyl)-1H-isoindole-1,3(2H)-dione 
• 82593-25-7 4-phenylbut-3-enylamine 
• 13214-66-9 4-phenyl-1-butylamine 
• 7515-38-0 (E)-4-phenylbut-3-en-1-amine 
• 93085-47-3 (Z)-4-phenylbut-3-en-1-amine 

Relevant articles and documents

Directed Nickel-Catalyzed Diastereoselective Reductive Difunctionalization of Alkenyl Amines

We report herein an intermolecular syn-arylalkylation and alkenylalkylation of alkenyl amines with two different organohalides (iodides and bromides) using Ni(II) catalyst. The cleavable bidentate quinolinamide is utilized after extensive directing group screening to enable olefin difunctionalization with high levels of regio-, chemo-, and diastereocontrol. This general and practical protocol is compatible with α- or β-substituted terminal alkenes and internal alkenes, providing rapid access to branched aliphatic amines bearing two skipped and vicinal stereocenters with high diastereoselectivities that would otherwise be difficult to synthesize.

Synthesis and pharmacological characterization of novel 6-fluorochroman derivatives as potential 5-HT(1A) receptor antagonists

A series of novel 6-fluorochroman derivatives was prepared and evaluated as antagonists for the 5-HT(1A) receptor. N-2-[[(6-Fluorochroman-8- yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamine (3; J. Med. Chem. 1997, 40, 1252- 1257) was chosen as a lead, and structural modifications were done on the aliphatic portion of the chroman ring, the tether linking the middle amine and the terminal aromatic ring, the aromatic ring, and lastly the amine. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT(1A) receptor, some of which were selective with respect to α1-adrenergic and D2-dopaminergic receptors. The antagonist activity of the compounds was assessed in the forskolinstimulated adenylate cyclase assays in CHO cells expressing the human 5-HT(1A) receptors. Among the modifications attempted, introduction of an oxo or an optically active hydroxy moiety at the chroman C-4 position was effective in ameliorating the receptor selectivity. Six analogues were selected through the in vitro screens and further evaluated for their in vivo activities. A 4-oxochroman derivative (31n), having a terminal 1,3- benzodioxole ring, demonstrated antagonist activities toward 8-OH-DPAT- induced behavioral and electrophysiological responses in rats.